What is Wedbush’s Forecast for AnaptysBio FY2024 Earnings?

AnaptysBio, Inc. (NASDAQ:ANAB) – Investment analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of AnaptysBio in a research note issued on Tuesday, November 5th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings of ($5.22) per share for the year, up from their previous forecast of ($6.65). Wedbush currently has a “Outperform” rating and a $42.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.84) per share. Wedbush also issued estimates for AnaptysBio’s Q4 2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($3.53) EPS.

Several other research firms have also weighed in on ANAB. UBS Group raised their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright decreased their target price on AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday. Guggenheim lifted their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Truist Financial upped their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $55.45.

AnaptysBio Trading Down 0.8 %

ANAB stock opened at $21.31 on Friday. The firm has a market cap of $584.53 million, a PE ratio of -3.36 and a beta of -0.24. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31. The company has a fifty day simple moving average of $32.66 and a 200 day simple moving average of $29.84.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors have recently bought and sold shares of ANAB. Frazier Life Sciences Management L.P. lifted its holdings in shares of AnaptysBio by 140.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares during the period. Assenagon Asset Management S.A. lifted its stake in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the period. StemPoint Capital LP boosted its holdings in AnaptysBio by 499.0% during the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock valued at $6,070,000 after purchasing an additional 224,548 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of AnaptysBio in the 3rd quarter valued at approximately $8,874,000. Finally, Victory Capital Management Inc. grew its stake in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the period.

Insider Activity

In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,440 shares of company stock valued at $892,936. Insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.